Articles On Impression Healthcare (ASX:IHL)

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Incannex Healthcare’s subsidiary Clarion Clinics will be the first dedicated psychedelic-assisted psychotherapy business in Australia and is expected to open its doors to patients later this year. Medicinal cannabis and psychedelic therapi...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Incannex Healthcare (ASX: IHL) has broken new ground in the emerging field of psychedelic therapies by signing a lease for Australia’s first psychedelic-assisted psych...

ImpediMed gets clearance from the US FDA for its SOZO Pro bioimpedance spectroscopy SOZO Pro offers a new, higher standing weight capacity compared to SOZO Incannex’s subsidiary to open a clinic to provide psychedelic-assisted psychotherap...

Results from a Phase-1 clinical of Incannex’s anti-inflammatory drug IHL-675A in healthy volunteers adds to the company’s confidence in proceeding with assessment in patients with inflammatory diseases. Medicinal cannabis and psychedelic t...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage psychedelic and medical cannabinoid pharmaceutical company Incannex Healthcare (ASX: IHL) has received final results from a phase 1 clinical trial under...

The All Ordinaries Index (ASX: XAO) is having a rough session on Thursday, but two stocks are defying the slump. While the All Ords is falling 0.4% to 7,472.9 points, these stocks are leaping as much as 7% on the back of strong quarterly u...

The S&P ASX 200 closed 0.35% lower, while the S&P XEC closed down 0.59% following lead of US markets RBR Group signals a restart to the stalled development of the Rovuma LNG mega project in northern Mozambique Incannex Healthcare...

The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week...

Incannex has made a key appointment as it works to advance its CannQuit-N (Nicotine), CannQuitO (Opioid) and Renecann products in the USA and EU. Medicanal cannabis and psychedelic therapies company, Incannex Healthcare (ASX: IHL) has anno...

Incannex (IHL) appoints Quest Pharmaceutical Services (QPS) to provide regulatory advice and manage its clinical trials for its patented drugs, CannQuit and ReneCann QPS is drafting pre-investigational drug submissions for the European M...

The Swiss government has moved quickly to shore up its uniqueness as a centre of commerce – albeit one where the banks eat each other – and hurriedly green-lit (no pun) plans to legalise the sale and consumption of cannabis in Zurich, Switz...

IHL is undergoing a pivotal point in its journey as a company moving from pure research to service delivery as Australia becomes the first country to recognise psychedelics as medicine. Incannex Healthcare (ASX: IHL) has announced that it h...

Incannex Healthcare (IHL) announces plans to launch psychedelic-assisted psychotherapy clinics in Australia and overseas They will be led by Australia’s leading psychedelics experts, with the first clinic expected to open in Melbourne th...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Incannex Healthcare (ASX: IHL), a clinical-stage psychedelics and cannabinoid pharmaceutical development company, has announced plans to commercialise its psychedelic-...

Telix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas   Telix Pharma (ASX:TLX) announced the US FDA has a...

Even though specific data from the PsiGAD trial cannot yet be released until the trial is completed, positive interim results of the Phase-2 clinical trial has given Incannex the encouragement to commence drafting an FDA IND application Inc...

Incannex Healthcare (IHL) projects its clinical trial will show a “statistically significant benefit” of psilocybin to treat general anxiety disorder Following an interim review of study data, IHL predicts there is an 85 per cent chance...

This content is created by Smallcaps Authors. [Author : Danica Cullinane] Incannex Healthcare (ASX: IHL) has emerged from a trading halt with news that its psychotherapy program to treat generalised anxiety disorder (GAD) has achieved pro...

Trading in ASX 300 cannabis stock Incannex Healthcare Ltd (ASX: IHL) has been suspended at the company’s request today. This follows Incannex shares going into a trading halt shortly after the market open on Friday. The Incannex share pr...

Aussie bourse has worst day since November 3 with S&P ASX 200 down 2.28% Even darling lithium stocks are down on declining prices in China Magnum Mining & Exploration soars 60% on positive metallurgical test work So it’s Friday...

ASX cannabis stocks provide a valuable service to the many thousands of Australians who benefit from the legal, medicinal benefits of their product. All told, the cannabis shares have grown, cured, and prepared medicinal marijuana products...

ShareCafeASX closes 0.4% higher but ends week 0.3% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.39 per cent higher at 7,283.60, supported by gains in mining and energy stocks, which were boosted by hopes of increas...

ASX 300 cannabis share Incannex Healthcare Ltd (ASX: IHL) is soaring today after the company announced some positive news. The Incannex share price is currently 14 cents, up 11.54% for the day so far. Let’s see what’s happening. What ne...

Incannex Healthcare [ASX:IHL], the medical cannabis and psychedelic drug developer, released an update about a cGMP-grade psilocybin drug product it will create with a drug company, Catalent. Catalent is a technology, drug, and biologic com...

03 Mar 2023 - A snapshot of the stocks on the move featuring Antilles Gold (ASX:AAU), Incannex (ASX:IHL) and Australian Gold and Copper (ASX:AGC).

ShareCafeStocks of the Hour: AAU, IHL, AGC                    Antilles Gold (ASX:AAU) has confirmed high grade copper at their El Pilar Oxide Deposit. Mr Brian Johnson, Executive Chairman of Antilles Gold, said that activities in Cuba...

ShareCafeASX 0.3% higher at noon after big gains from US stocks overnight by Peter Milios   A day after the release of the decreasing housing approvals, new owner-occupier first home loan commitments in Australia dropped by 8.1 per cent to...

Incannex Healthcare (IHL) engages NYSE-listed Catalent to manufacture a psilocybin drug product for its clinical trials on generalised anxiety disorder The companies will develop a current good manufacturing practice (GMP)-grade psilocyb...

As Australia becomes the first country to recognise psychedelics as medicine, Incannex Healthcare is going to start manufacturing its own psilocybin drug product, boosting both trial and commercial opportunities. Clinical stage pharmaceuti...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Incannex Healthcare (ASX: IHL) has reached another milestone in progressing its psilocybin drug product by engaging Catalent to formulate and manufacture the drug for...

The ASX is set to open higher on Friday, tracking overnight’s movement in New York Tesla dropped 6% after an uninspiring Investor Day Crypto bank Silvergate Capital says it may not survive   The ASX is poised to open higher on Friday, in...

Having closed a $13 million placement in December for the development of its alternative medicine pipeline, Incannex Healthcare (ASX: IHL) has today announced a partnership with New Jersey-based Catalent for the manufacture of a psilocybin-...

The ASX slid to close flat today, after realising we were in danger of making some money Materials and Energy enjoyed a boost from Chinese manufacturing data Retail theft rates have soared as the cost of living crisis hits hard around the...

Incannex’ Phase-2 trial can potentially open the door to a US$125 billion market for the treatment of rheumatoid arthritis, inflammatory lung conditions, and inflammatory bowel disease. Following a successful Phase-1 trial, medical cannabis...

Incannex (IHL) kicks off a phase two trial of its IHL-675A drug to treat rheumatoid arthritis following a successful phase one trial and animal studies IHL-675A comprises a combination of hydroxychloroquine and cannabidiol (CBD) to treat...

Medicinal cannabinoid and psychedelic medicine company Incannex Healthcare (ASX:IHL) has commenced a Phase 2 clinical trial to assess the safety and efficacy of its anti-inflammatory combination drug IHL-675A in patients with rheuma...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Medicinal cannabinoid and psychedelic therapies developer Incannex Healthcare (ASX: IHL) has commenced a Phase 2 clinical trial to assess the safety and efficacy of it...

The TGA has changed its classification of psilocybin and MDMA As a result, Australia has become the first country in the world to recognise psychedelics as medicine ASX psychedelic related stocks surged on Monday   Australia has become th...

Independent analysis has started of Incannex’s Phase 2 clinical trial to assess its psilocybin-assisted psychotherapy for treatment  of  generalised  anxiety disorder  (GAD).  The Incannex (ASX:IHL) phase 2 PsiGAD1  clinical  trial has ach...

Incannex Healthcare (IHL) achieves interim milestone in its clinical trial to treat generalised anxiety disorder Twenty-nine patients of the 45 enrolled have now completed primary endpoint assessments as part of the company’s psilocybin...

The ASX is set to drift higher at the open Goldman Sachs’ profit tumbled by 68pc The ECB is reportedly mulling over softening its rates stance   Aussie shares are set to drift higher at the open on Wednesday. At 8am AEDT, the ASX 200 Jan...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Incannex Healthcare (ASX: IHL) has announced that the PsiGAD1 clinical trial to assess its psilocybin-assisted psychotherapy for the treatment of generalised anxiety d...

The Australian legalisation of medical cannabis in 2016 launched a flood of new companies to the ASX. While the sector is relatively young, a growing patient base and the possibility of recreational legalisation are proving to be full of...

ASX Health sector has ended its upward trend falling 0.7% in the past five days in line with broader markets As the end of 2022 approaches several ASX health stocks announce capital raising results to secure funding Healius announces sal...

Medcan and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has filed a provisional patent application directed to the use of lead drug IHL-42X for the treatment of obstructive sleep apnoea (OSA). The application is the lat...

Incannex Healthcare (IHL) has filed a provisional patent application for the use of IHL-42X for the treatment of obstructive sleep apnoea (OSA)Incannex says it intends to use the application to pursue further patent protection for its clini...

Incannex Healthcare (IHL) has received firm commitments to raise $13 million through an institutional placement The placement will be undertaken by a small consortium of US and international investors who IHL says are known for providing lo...

ASX 200 gets golden, adds 1% Small cap index rises 1.05% Greenstone finds yellow stone What you need to know first up is that the benchmark ASX200 is doing well. It’s ahead by about 0.9% with 10 minutes of play left in the session. Even...

The Incannex Healthcare Ltd (ASX: IHL) share price went nowhere on Thursday after the company requested a trading halt before the market open. The Incannex share price was 23 cents at the close yesterday. Let’s find out what’s happening...